Thermo Fisher Scientific Inc. – CRI Report

Global Companion Diagnostics for Oncology Market Research Report—Forecast till 2027

admin — Wed, 28 Apr 2021 06:54:29 +0000

Global Companion Diagnostics for Oncology Market Research Report—Forecast till 2027

Market Synopsis
Global Companion Diagnostics for Oncology Market is expected to witness a substantial market expansion at a CAGR of 22.57% during the review period of 2020 to 2027. The global market growth is attributed to rising R&D and drug-diagnostic co-development, increasing preference for personalized medicine, the growing global incidence of cancer, and rising product approvals by major players.
The global companion diagnostics for oncology market owing to the highest market value of USD 1,603.16 Million in 2019. Major market players are focusing on various growth strategies such as product launches, product expansion, and business expansions to serve the increasing demand for personalized medicine. These product launches and business expansion are expected to set the growth of the companion diagnostics for the oncology market during the review period. However, the lack of reimbursement in developing regions is expected to restrain the market growth during the review period.
Market Segmentation
Global Companion Diagnostics for Oncology Market has been classified into Products & Services, Technology, Indication, and End User.
Based on product & service, has been classified into assays, kits & reagents, and software & services.
In terms of technology type, the global companion diagnostics for the oncology market is classified into polymerase chain reaction (PCR) and next-generation sequencing (NGS).
In terms of indication segment, the global market has been categorized into breast cancer, lung cancer, colorectal cancer, gastric cancer, melanoma, and others. Based on end-user, the market is classified into pharmaceutical & biopharmaceutical companies, laboratories, contract research organizations, and others.
Regional Analysis
Geographically, the Global Companion Diagnostics for Oncology Market is classified into four main regions, namely the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is likely to drive the largest market owing to the major share in 2019 and it is expected to command the market during the forecast period. The regional market is attributed to the high prevalence rate of cancer and other chronic disorders and growing healthcare expenditure.
Europe is expected to register the second-largest market share owing to the existence of many companies, rising research and development activities to develop targeted drug therapy for a cancer patient, and rising per capita income increases the preference for personalized medicine.
Asia-Pacific is anticipated to be the fastest-growing regional market during the review period owing to the increasing number of cancer patients and the growing presence of market players. Furthermore, the increasing research funding, increasing investments by pharmaceutical and biotechnology companies, and rising awareness about personalized therapeutics in several APAC countries are expected to propel the growth of the Asia-Pacific market.
The Middle East & Africa is expected to register a steady market growth during the review period owing to the emerging market in countries such as Kuwait, the UAE, and Saudi Arabia.
Major Players
The Key Players in the Global Companion Diagnostics for Oncology Market include Agilent Technologies Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd, BioMérieux SA, Foundation Medicine, Archer Dx, Qiagen, Thermo Fisher Scientific Inc., Amoy Dx, and Abbott.
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Global Radiation Therapy in the Oncology Market: Focus on Radiation Therapy Systems, Product Regulation, Key Strategies and Developments, Market Dynamics, 15 Company Profiles, and 12 Countries Data and Cross Segmentation – Analysis and Forecast, 2021-2031

The post Global Companion Diagnostics for Oncology Market Research Report—Forecast till 2027 first appeared on CRI Report.

Global Capillary Blood Collection Devices Market Research Report – Forecast Till 2023

admin — Fri, 28 Dec 2018 02:47:33 +0000

Market Analysis
Blood Collection for testing assumes a fundamental role in an effective medical treatment at the hospitals, healthcare and diagnostic centers all over the world. Blood test accumulation method incorporates a chain of sequence, and each sequence of this grouping is very imperative to keep up high-quality clinical outcomes. Global capillary blood collection devices market is anticipated to grow at a CAGR of 10.0% during the forecast period 2017–2023.
It has been noticed that the medical device regulation is the key factor driving the growth of the capillary blood collection devices market. Control of the usage of a medical device must be upgraded and improvised to protect the well-being of the patient. It must be ensured that high-quality products and effective technologies reach the patients. Developing interest for analysis of chronic diseases, the rising prevalence of diabetes, and expanding geriatric populace are additionally energizing the market development. However, the higher risk related to the capillary blood assortment technologies leading to blood contaminations may restrict the growth of the capillary blood collection devices market.
Market Segmentation
The global capillary blood collection devices market is divided on the basis of its type of devices, material, and end-user industry. On the basis of its type of devices, the global capillary blood collection devices market is bifurcated into lancets, blood collecting tubes and collector, and warming devices. Based on its material, the global market is classified into glass, plastic, stainless steel, and others. Based on its end -user, the market is sectioned into clinics, hospitals, home diagnostics, diagnostic centers and pathology laboratories, and others.
Regional Analysis
Geographically, the global capillary blood collection devices market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.
Major Players
Some of major players in the capillary blood collection devices market include companies like F. Hoffmann-La Roche AG, Abbott Laboratories, Danaher Corporation, Novo Nordisk A S, Medtronic PLC, B. Braun Melsungen AG, Becton Dickinson and Company, Thermo Fisher Scientific Inc., Ypsomed Holding AG, Terumo Corporation, HTL-STREFA S.A., Sarstedt AG & Co, Greiner Bio-One, Owen Mumford Ltd., Improve Medical, Weigao Group, Chengdu Rich Science Industry Co., Ltd., Nipro, Weihai Hongyu Medical Devices, Medigard, and others.

The post Global Capillary Blood Collection Devices Market Research Report – Forecast Till 2023 first appeared on CRI Report.

Global Creatinine Test Market Research Report – Forecast to 2023

admin — Tue, 04 Dec 2018 07:30:43 +0000

Introduction
Creatinine test is a type of blood test that measures the level of creatinine in the blood. When creatine, an amino acid found in the muscle, breaks down, it forms a waste product known as creatinine. It is a waste product that the kidneys normally eliminate from the body. Creatinine levels in the blood help to determine if the kidneys are working well. The growing prevalence of chronic kidney diseases, technological advancements in the kidney function testing, and initiatives taken by the government to control chronic kidney diseases are expected to drive market growth. According to a study published by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in December 2016, the overall prevalence of chronic kidney diseases (CKD) in the US was approximately 14%. However, false estimates of creatinine tests may hamper the growth of the market.
The global creatinine test market is expected to reach a market value of USD 604.55 million by 2023 from USD 407.41 million in 2016 and is expected to register a CAGR of 5.8% during the forecast period from 2017 to 2023. In 2016, the Americas held the highest share of the market at 35.4%, followed by Europe and Asia-Pacific with shares of 31.4% and 20.5%, respectively. The increasing prevalence of kidney diseases worldwide is expected to increase the growth of the market during the forecast period.
The global creatinine test market is segmented into test type, product type, application, end user, and region.
The global creatinine test market, by test type, is segmented into blood test, urine test, and creatinine clearance test.
The global creatinine test market, by product type, is segmented into consumables and instruments.
The global creatinine test market, by application, is segmented into urinary tract obstruction, renal failure, kidney cancer, and glomerulonephritis.
By end user, the global creatinine test market is segmented into hospitals and clinics, diagnostic centers, and research institutes.
The global creatinine test market is expected to have a value of USD 604.55 million by 2023 from USD 407.41 million in 2017 and is expected to register a CAGR of 5.8% during the forecast period from 2017 to 2023.
Key Players
Siemens AG, Abbott, Thermo Fisher Scientific Inc, Abcam plc, F. Hoffmann-La Roche AG, Nova Biomedical, ACON Laboratories, Inc., OPTI Medical Systems, URIT Medical, Quest Diagnostics, ARKRAY, Inc., and Danaher
Study objectives
• To provide a detailed analysis of the market structure along with the forecast of various segments and sub-segments of the creatinine test market
• To provide insights into factors affecting the market growth
• To analyze the global creatinine test market based on various tools such as supply chain analysis and Porter’s five force analysis
• To provide historical and forecast revenue of market segments and sub-segments with respect to regions and their respective key countries
• To provide the country-level analysis of the market with respect to the current market size and future perspective
• To provide country-level analysis of the market for segments by test type, product type, application, end user, and region
• To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market
• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the creatinine test market
Target Audience
• Diagnostic Centers
• Research and Development (R&D) Companies
• Government Research Institutes
• Academic Institutes and Universities
Key Findings
• The global creatinine test market is expected to reach USD 604.55 million by 2023 at a CAGR of 5.8 % from 2017 to 2023
• On the basis of test type, blood tests are expected to account for the largest market share at a CAGR of 5.32% by 2023
• On the basis of product type, consumables are expected to account for the largest market share at a CAGR of 5.59% by 2023
• On the basis of application, urinary tract obstruction is expected to account for the largest market share at a CAGR of 5.10% by 2023
• On the basis of end user, hospitals and clinics are expected to account for the largest market share at a CAGR of 5.30% by 2023
• The Americas is expected to hold the largest share of the global creatinine test market at a CAGR of 5.91% by 2023
• Asia-Pacific is the fastest growing market, which is expected to register a CAGR of 6.33% by 2023
Regional Analysis
• Americas
o North America
 US
 Canada
o South America
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o India
o Australia
o Republic of Korea
o Rest of Asia-Pacific
• Middle East & Africa
o Middle East
o Africa

The post Global Creatinine Test Market Research Report – Forecast to 2023 first appeared on CRI Report.